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Abstract Productivity costs can strongly impact cost-ef-
fectiveness outcomes. This study investigated the impact in
the context of expensive hospital drugs. This study aimed
to: (1) investigate the effect of productivity costs on cost-
effectiveness outcomes, (2) determine whether economic
evaluations of expensive drugs commonly include pro-
ductivity costs related to paid and unpaid work, and (3)
explore potential reasons for excluding productivity costs
from the economic evaluation. We conducted a systematic
literature review to identify economic evaluations of 33
expensive drugs. We analysed whether evaluations in-
cluded productivity costs and whether inclusion or exclu-
sion was related to the study population’s age, health and
national health economic guidelines. The impact on cost-
effectiveness outcomes was assessed in studies that in-
cluded productivity costs. Of 249 identified economic
evaluations of expensive drugs, 22 (9 %) included pro-
ductivity costs related to paid work. One study included
unpaid productivity. Mostly, productivity cost exclusion
could not be explained by the study population’s age and
health status, but national guidelines appeared influential.
Productivity costs proved often highly influential. This
study indicates that productivity costs in economic
evaluations of expensive hospital drugs are commonly and
inconsistently ignored in economic evaluations. This war-
rants caution in interpreting and comparing the results of
these evaluations.
Keywords Productivity costs  Indirect costs  Economic
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Introduction
The development of new and expensive health care tech-
nologies has increased the pressure on national health care
budgets. Hence, there is a growing focus on whether new
interventions offer value for money in terms of cost-ef-
fectiveness. This may especially be the case for very ex-
pensive interventions with an expected high budget impact,
such as newly developed drugs administered in a hospital
setting (e.g. new chemotherapies for cancer patients).
In order to determine the relative cost-effectiveness of
new expensive interventions, many countries prescribe
conducting a health economic evaluation. In an economic
evaluation the health effects of two or more treatments are
compared to their respective costs. Most countries that
prescribe economic evaluations have formulated national
health economic guidelines stipulating how these evalua-
tions should be conducted. National guidelines are likely
(and intended) to influence how economic evaluations are
conducted in practice. One important aspect in such guide-
lines is the perspective the evaluation should take. Economic
evaluations adopting a health care perspective include costs
falling on the health care budget only, whereas economic
evaluations adopting a societal perspective aim to include all
relevant effects and costs, regardless of who bears the costs
and who receives the benefits. Approximately half of the
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national guidelines on the ISPOR ‘pharmacoeconomic
guidelines around the world’ website [1] prescribe taking a
health care perspective (at least for the base case scenario)
and the other half a societal perspective or a health care and
societal perspective. However, most countries prescribing a
health care perspective allow presenting additional cost-ef-
fectiveness scenarios that include broader societal costs,
such as productivity costs. England and Wales, where the
National Institute for Health and Care Excellence (NICE)
operates [2] and New Zealand, were noticeable exceptions:
those explicitly forbid including productivity costs in any of
the presented analyses.
In the health economic literature, adopting a societal
perspective is often advocated [3–7]. However, it is cer-
tainly not an undisputed choice [8].1 This lack of consensus
regarding the appropriate perspective has likely contributed
to the differences between national health economic
guidelines. Interesting developments in this context are the
likely changes in the United Kingdom (UK) where a shift
to a value based pricing system is foreseen. Within the new
system, economic evaluations should be conducted from
the societal perspective instead of the currently applied
health care perspective [9], which implies a major change
in standpoint. Given the fact that the UK is one of the
leading countries in performing and using economic
evaluations in health care decision-making, this change
may lead to more economic evaluations taking a societal
perspective.
An important question is how such a difference in per-
spective could potentially affect decision-making. This
obviously depends on the additional cost categories in-
cluded in the analysis when performed from a societal
perspective and their relative magnitude. The most influ-
ential cost category in that context may be productivity
costs. Productivity costs can be defined as ‘‘costs associ-
ated with production loss and replacement costs due to
illness, disability and death of productive persons, both
paid and unpaid’’ [10]. Productivity costs can be quite in-
fluential on final outcomes of economic evaluations. For
instance, in economic evaluations of treatments for de-
pression, such costs, on average, reflect more than half of
total costs, often strongly influencing incremental costs
and, in turn, cost-effectiveness [11]. The inclusion of pro-
ductivity costs (and the choice of perspective) thus can
influence the allocation of scarce health care resources
across diseases and patients if the latter is—at least to some
extent—determined by incremental cost-effectiveness.
Even though half of the national health economic
guidelines prescribe a societal perspective and productivity
costs and savings can be substantial, previous studies
suggest that, depending on the types of interventions and
economic evaluations studied, not more than 8–31 % of
economic evaluations actually include productivity costs
related to paid work [11–13]. The inclusion of production
loss related to unpaid labour seems even less common,
although this has rarely been studied [13]. If productivity
costs (related to both paid and unpaid labour) are indeed
often ignored in economic evaluations, it is important to
understand why this is the case and how final outcomes are
influenced by ignoring these costs. It has been suggested
that the choice regarding inclusion of productivity costs
may sometimes be strategically driven by their expected
impact on cost-effectiveness outcomes [11]. However, the
exclusion of productivity costs may also be related to more
pragmatic issues. In the case of expensive hospital drugs,
for instance, it may be that productivity costs have a
relative small impact on outcomes, for instance due to very
high medical costs and (regarding productivity costs re-
lated to paid work) the relatively high age of patients.
Under such circumstances, omitting productivity costs (or
applying a health care perspective) potentially would not
affect final cost-effectiveness ratios substantially. This,
however, has never been investigated to our knowledge.
Therefore, this study sought to answer the question
whether inclusion of these costs in expensive drugs studies
is influential, in other words, whether they have a sub-
stantial impact on cost-effectiveness outcomes. Moreover,
it aimed to determine whether cost-effectiveness studies of
expensive drugs administered in a hospital setting normally
include productivity costs related to paid and unpaid work.
In addition, we aimed to explore how productivity costs
were calculated in economic evaluations, i.e. which
methodology was used to estimate productivity costs. Fi-
nally, we explored potential reasons for excluding pro-
ductivity costs from the economic evaluation, such as
countries’ health economic reimbursement submission
guidelines as well as age and health status of the studies’
patient populations.
To meet the study objectives, we conducted an extensive
systematic review of economic evaluations of 33 distinct
expensive drugs administered in a hospital setting.2 The
effect of including productivity costs on the cost-effec-
tiveness outcomes was assessed by investigating those
studies that included productivity costs and evaluating the
impact of these productivity costs on final results.
Before describing and discussing the methods and re-
sults of our systematic review, in the Background Section
we first discuss productivity costs and the potential
1 For further discussion on perspectives in economic evaluations see
for instance Brouwer et al. [14], Claxton et al. [8], Johannesson et al.
[3] and Jonssen [4].
2 These drugs were selected from the Dutch ‘expensive hospital drug
list’ [31]. Until recently, hospitals in the Netherlands received
additional financing for drugs placed on this list.
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explanations for the poor inclusion of productivity costs in
economic evaluations of health care interventions.
Background
Commonly, four categories of costs are distinguished in
health economic evaluations: direct costs within health
care, direct costs outside health care, indirect costs within
health care and indirect costs outside health care [6, 7].
This latter category includes productivity costs which are
an important cost-category and are widely recognised as
real societal costs and potentially influential [13–15].
Nevertheless, the scarce available evidence suggests that
these costs remain excluded from the majority of actual
economic evaluations [11–13, 16]. Factors contributing to
the neglect of productivity costs in economic evaluations
can relate to the principles on which the economic
evaluation is based, or pragmatic considerations throughout
the execution of the economic evaluation. Pragmatic fac-
tors that contribute to ignoring productivity costs in eco-
nomic evaluations could be a lack of time, data, research
experience [17], or a (perceived) lack of relevance.
Moreover, the lack of standardization of productivity cost
methodology is likely to be of influence. Recently, some
papers were published aimed at increasing standardization
in this area [18–21].
Relevance of including productivity costs
in economic evaluations
Following ‘the rule of reason’, which states that if costs
‘‘…are trivially small or do not differ across regimens,
their inclusion will have little effect on the final results of
an analysis, and they may therefore be omitted at the
analyst’s discretion’’ [6], productivity costs may be seen as
irrelevant in several circumstances.
First, if productivity is not affected by some treatment,
including productivity related costs would be superfluous,
such as with some treatments aimed at very mild conditions
or treatments aimed at very severe conditions in which pa-
tients are fully impaired without expectation of returning to
paid or unpaid work (which may be the case for some pa-
tients receiving very expensive drug treatments in the hos-
pital). In most cases, however, whether health interventions
will affect patients’ productivity is difficult to predict.
Second, following to the rule of reason, productivity
cost inclusion would be irrelevant if productivity is un-
changed relative to the comparator (i.e. if productivity
changes are similar in both the intervention and comparator
groups), since productivity costs will then not change in-
cremental cost-effectiveness ratios. For most interventions,
determining up front whether productivity costs in both
study arms will be equal is difficult, and excluding pro-
ductivity costs on this ground is thus debatable.
Third, and also related to the rule of reason, productivity
costs related to paid work may also be seen as less relevant
for economic evaluations of interventions targeted at peo-
ple not of working age. For instance, if most of the patients
receiving an intervention are above retirement age, pro-
ductivity losses related to paid work may be negligible.
Note, however, that this is not the case for losses related to
unpaid work. Treatments targeted at very young patients
could affect future productivity, rendering productivity
costs an important factor. Whether such effects are con-
sidered important to economic evaluations also depends on
the valuation method chosen: related costs or savings
should be included if using the human capital approach
[22] but not if using the friction cost approach [23].
A final rationale for ignoring productivity costs in line
with the rule of reason might be the expectation that these
costs are not very influential if direct costs are relatively
high. This might be the case in economic evaluations of
(very) expensive drugs, especially when these drugs are
administered in a (costly) inpatient setting. When, as a rule,
productivity costs have little effect on cost-effectiveness
outcomes in economic evaluations of expensive hospital
drugs, they might be excluded a priori, limiting the burden
to patients, and saving time and other resources. If the costs
are influential (as they are in some areas [11, 24, 25]),
ignoring productivity costs up front could lead to sub-op-
timal decision-making.
Ethical concerns regarding the inclusion
of productivity costs in economic evaluations
Next to questions on the relevance of productivity costs in
some situations, the inclusion of productivity costs may
lead to equity concerns, because their inclusion may favour
reimbursement of health interventions targeted at the
working population [26, 27]. If such interventions produce
substantial societal savings by improving productivity
levels, including productivity costs may result in more
favourable cost-effectiveness outcomes than when similar
interventions are used in less productive populations (e.g.
very young or elderly). However, it is questionable whether
ignoring the existence of costs and savings outside the
health care sector is the proper solution to such ethical
concerns, since it denies decision makers the opportunity to
make well-informed decisions and balance potential sav-
ings with the equity implications of their decisions. Nev-
ertheless, equity concerns are explicitly mentioned in some
national health economic guidelines stipulating how to
conduct economic evaluations for reimbursement of health
interventions. For instance, in Australia [28] and New
Zealand [29] the health economic guidelines prescribe a
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health care perspective rather than a societal perspective,
based on equity arguments.
A number of reasons highlighted above may affect the
inclusion of productivity costs in economic evaluations of
expensive hospital drugs. We therefore set out to review the
literature in order to investigate this further, as highlighted
next.
Methods
Review of economic evaluations of expensive
hospital drugs
We performed an extensive systematic review of all 33
drugs on the Dutch ‘expensive drug list’ in June 2009 to
identify any economic evaluation. Table 1 presents the
drugs and some examples of which diseases the drugs on the
list are prescribed for. This list was chosen as the basis for
the review, since drugs on this list pose a considerable
burden on the health care drug budget. Although the Dutch
list was used as a basis, drugs on this list pose a substantial
burden on the health care budget in other Western countries
as well. See for instance the paper of Hofman et al. [30]
about future drug expenditure in hospitals in the United
States. A drug is only eligible for placement on this list if the
drug costs are very high (total drug expenses exceed a cer-
tain threshold) and the drug is administered within a hospital
setting. Until recently, for drugs on the list, hospitals (nor-
mally subject to a yearly fixed budget) received additional
financing in order to remove financial barriers which might
stop patients from receiving these drugs [31].
We used the Cochrane Library and PubMed databases
with a publication date limit of January 1998 to June 2009.
Queries used for the database search were the drugs’
names and ‘‘cost’’ or ‘‘costs’’. Inclusion criteria were (1)
unique scientific articles in peer-reviewed journals in Eng-
lish, and (2) titles with terms or phrases such as cost(s),
budget, economic, financial, price, money, dollar, economy,
expenditure, pay, expense, fund, resource, reimbursement,
consumption, or expensive. After excluding any reviews,
we read abstracts of the remaining articles to determine if
they were indeed economic evaluations. Finally, the full
texts of the remaining articles were examined (with the
exception of those unavailable in the Netherlands or British
Library). Title and abstract searches were independently
undertaken by two researchers. Full text examinations were
carried out by two people in close collaboration.
Inclusion of productivity costs
After identifying economic evaluations of expensive drugs,
we investigated whether they included productivity costs
related to paid or unpaid work and, if they did, how pro-
ductivity losses were measured and valued. In order to do
so we read the method sections of the papers and we ex-
amined the tables presenting the costs included in the in-
dividual studies.
Next, we explored whether the choice of including or
excluding productivity costs is related to (1) age—working
age of the patient population, (2) the patient population’s
ability to work based on disease severity and (3) national
health economic guidelines. Where possible we extracted
the reported average or median age and the illness of the
patients in the study populations. If the age of the patients
was not reported in the paper, such as in several health
economic modelling papers, we examined the paper re-
porting on the original clinical trial on which the modelling
study was based. To explore whether age may explain the
inclusion of productivity costs related to paid work, we
assumed that at least a considerable part of a study
population would be of working age if the average age of
the study population was between 18 and 70. Subsequently,
it was investigated whether inclusion or exclusion of pro-
ductivity costs was related to the (estimated) health related
ability to work, or the likelihood that at least a part of the
patient population in individual studies would lose or re-
gain the ability to work (in comparison to the control
group). These estimations were based on a medical doc-
tor’s expert opinion regarding the severity of disease of the
patient populations as extracted from the papers (e.g., in
the case of metastatic cancer it was assumed that (most)
patients would not be able to perform paid work regardless
of treatment). We also examined whether studies aligned
with their national health economic guidelines regarding
productivity costs. National and regional health economic
guidelines were retrieved through the ISPOR ‘pharma-
coeconomic guidelines around the world’ website [1].
Where possible, the original guideline documents were
studied. If the guidelines were not available in English we
followed the ISPOR ‘‘Key Features’’ pages. If guidelines
were non-existent or not listed, they were labelled ‘‘un-
known’’ and productivity cost exclusion could not be re-
lated to a recommended perspective.
The impact of productivity costs on costs and cost-
effectiveness
For the studies that included productivity costs, the per-
centage of total cost accounted for by productivity costs
was calculated and reported. We then excluded produc-
tivity costs from the study’s incremental cost-effectiveness
ratio(s) to analyse the impact of productivity costs on cost-
effectiveness outcomes. We described whether inclusion of
productivity costs led to change in incremental cost-ef-
fectiveness and the magnitude of the change. For cost-
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minimization studies (where incremental effects are in-
significant) we examined only changes in incremental
costs. All prices were adjusted to 2009 euros using the
European Union Harmonized Indices of Consumer Prices
published by Eurostat [32].
Results
Review
The database search resulted in 2,157 articles in Pubmed
and 422 in the Cochrane Library, 834 of which were
doubles (Fig. 1). The number of doubles was quite high
because many economic evaluations included more than
one expensive drug and, as a consequence, appeared in
several of the database searches of the individual drugs.
Ten articles were not in English; 1,120 did not include an
economic term or phrase in the title; 15 were not available
in the Netherlands or British Library; 52 were not scientific
research articles; 89 were congress abstracts; 111 were
reviews; three did not evaluate one of the 33 drugs; and 96
could not be qualified as economic evaluations. This re-
sulted in 249 economic evaluations of drugs from the
Dutch expensive hospital drug list [31]. Of these, 22 (about
9 %) included productivity costs related to paid work and
only one of these [33] additionally included productivity
costs related to unpaid work. (See Online Resource for
details of the studies.) Of the 22 economic evaluations
including productivity costs, three were identified as cost
Table 1 Pharmaceuticals
included in the review (Dutch
expensive hospital drug list June
2009)
Drug name Example of prescription area
Docetaxel Breast cancer, lung cancer, prostate cancer
Irinotecan Colon cancer
Gemcitabine Bladder cancer, breast cancer, lung cancer
Oxaliplatin Colorectal cancer
Paclitaxel Bladder cancer, ovarian cancer, melanoma
Rituximab Leukemia, lymphomas
Infliximab Ankylosing spondylitis, Crohn’s disease, rheumatoid arthritis
Intravenous immunoglobulin Autoimmune diseases
Trastuzumab Breast cancer
Botulin toxin Several types of spasm
Verteporfin Macular degeneration
Doxorubicin liposomal Leukemia, several types of cancer
Vinorelbine Lung cancer, breast cancer
Bevacizumab Breast cancer, colorectal cancer, lung cancer
Pemetrexed Pleural mesothelioma
Bortezomib Multiple myeloma
Omalizumab Asthma
Ibritumomab Non-Hodgkin’s lymphoma
Pegaptanib Macular degeneration
Alemtuzumab Chronic lymphocytic leukemia, multiple sclerosis
Palifermin Leukemia, lymphomas
Drotrecogin-alfa Severe sepsis
Natalizumab Crohn’s disease, multiple sclerosis
Cetuximab Colon cancer
Ranibizumab Macular degeneration
Abatacept Rheumatoid arthritis
Voriconazole Invasive aspergillosis, invasive candidiasis
Methyl aminolevulinate Skin cancer
Panitumumab Colorectal cancer
Anidulafungin Invasive aspergillosis, invasive candidiasis
Caspofungin Invasive aspergillosis, invasive candidiasis
Temsirolimus Renal cancer
Temoporfin Head and neck cancer
Note that this is not a complete list of diseases for which these drugs are prescribed
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minimization analyses (CMA); [34–36] the remaining 19
were cost-utility analyses (CUA), where effects are ex-
pressed in quality adjusted life years (QALYs). Eight of the
22 economic evaluations including productivity costs in-
vestigated treatments for rheumatoid arthritis, 5 were about
ankylosing spondylitis, 3 were about breast cancer, 2
evaluated multiple sclerosis treatments, 1 was about col-
orectal cancer treatment, 1 was about ovarian cancer, one
was about asthma and one studied sepsis.
Inclusion of productivity costs: age, work ability
and health economic guidelines
Inclusion (or exclusion) of productivity costs of all 249
economic evaluations was compared with the study-
populations’ median or average age, the estimated work
ability and the health economic guidelines of the respective
countries. As can be seen in Table 2, most study-popula-
tions had an average age below 70 in both the studies
including and excluding productivity costs. Based on a
doctor’s opinion, the study populations of approximately
one-third of the studies excluding productivity costs were
expected not to be able to perform paid work regardless of
treatment.
Based on national health economic guidelines, for 56 of
the 249 economic evaluations, productivity cost inclusion
was not allowed (i.e. studies from England, Wales or New
Zealand) but four of the 56 included productivity costs
anyway [35, 37–39]. In all four studies the incremental
cost-effectiveness ratios (ICERs) decreased due to includ-
ing productivity costs. Information on the countries the
studies originated from and the perspective prescribed in
the health economic guidelines of these countries can be
found in Online Resource 1. Fourteen economic
Potenally relevant studies (n = 2579)
Studies more closely examined (n =615)
Studies included in tle scan (n =1735)
Economic evaluaons of relevant drugs (n = 249)
Studies excluded
• Not available in Dutch/Brish library (n = 15)
• No scienﬁc research arcle (n = 52)
• Congress abstracts (n = 89)
• Reviews (n =111)
• No relevant drugs included (n = 3)
• No economic evaluaon (n = 96)
Studies excluded
• No economic words in tle (n = 1120)
Studies excluded
• Double arcles (n = 834)
• Not in English (n = 10)
Fig. 1 Flow diagram of the
systematic literature review
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evaluations originated from countries for which no guide-
lines were available, only one of which included produc-
tivity costs [36]. In 74 economic evaluations, inclusion of
productivity costs was mandatory according to the relevant
health economic guidelines, but only 11 studies followed
the rule. Despite this low level of inclusion, Table 3 shows
that productivity costs were (as expected) more often in-
cluded in evaluations originating from countries with
guidelines prescribing inclusion. Only six of the 106
studies from countries in which productivity cost inclusion
is allowed but not required included the costs [40–45].
Productivity costs methodology
Three [39, 46, 47] of the 22 studies including productivity
costs provided no details on either the measurement of
productivity costs (e.g. using patient questionnaires or lit-
erature estimates), or the valuation (the valuation approach
used and the values attached to lost productivity).
Regarding the measurement of productivity costs, only
seven studies [36–38, 42, 48–51] described actual data
collection on productivity among the patient population,
but none of them specified the productivity costs mea-
surement instrument used. Two economic evaluations [34,
51] explicitly assumed that productivity would be
relatively unaffected in all study arms; i.e., productivity
costs were assumed not to vary. Consequently, in these
studies, productivity costs were not quantified.
With regard to the valuation of lost work, ten of the 22
studies [33–36, 38, 40–42, 45, 49] used average (age- and
gender-dependent) wage and employment rates to value
lost working time. In one study [44] it was assumed (based
on outcomes of a previous study) that productivity costs
would be either equal to the direct costs or three times the
direct costs. Another study [52] used employers’ annual
labour costs. The remaining ten studies [37, 39, 43, 46–48,
50, 51, 53, 54] did not specify the values used. Three
studies applied the friction cost approach [33, 34, 53].
These studies also applied the human capital approach.
Only four of the 17 remaining studies [38, 43, 49, 54]
explicitly mentioned applying the human capital approach.
We assumed that studies not clearly specifying their
method applied the human capital approach, which was
indeed in line with their descriptions of productivity cost
calculations. The one study that additionally included
productivity costs related to unpaid work based the cost
estimates on changes in household work and volunteer
work [33]. The time spent on unpaid work was valued at
the same rate as informal care (correcting for the costs
already included for household help and informal care).
Table 2 Patients’ ages and
health-related work ability
Studies including PC (n = 22) Studies excluding PC (n = 227)
Productive age (18–65)
Yes (mean age 18–70) 19 (86 %) 163 (72 %)
No (mean age[70) - 21 (9 %)
Unknown 3 (14 %) 42 (19 %)
Work ability based on severity of illness
Likely to be able to work 21 (95 %) 146 (64 %)
Doubtful 1 (5 %) 8 (4 %)
Unlikely to be able to work - 73 (32 %)
These estimations were based on a medical doctor’s expert opinion regarding the severity of disease of the
patient populations
PC productivity costs
Table 3 Productivity cost
inclusion and national health
economic guidelines
Perspectives in HE guidelines Economic evaluations Studies including PC % inclusion
Health care for base case 56 4 7
PC not allowed in any scenario
Health care for BC 74 4 5
PC allowed in additional scenarios
Societal 41 7 17
Societal and health care 33 4 12
Societal or health care 32 2 6
Unknown 13 1 8
Total 249 22 9
HE health economic, PC productivity costs, BC base case
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Productivity costs inclusion: the proportion of total
costs
We could not determine the proportion of total costs ac-
counted for by productivity costs for 11 of the 22 articles
due to a limited level of detail in the presented cost items.
Four of these 11 [39, 40, 42, 47] did not provide specifi-
cations regarding the amount of productivity costs and
seven only provided information on incremental produc-
tivity costs [37, 38, 43, 48, 49, 51, 52].
The remaining 11 articles provided information on the
absolute amount of productivity costs. In these 11 studies,
37 estimates were available of productivity costs related to
an intervention or comparator. Twenty-four of these esti-
mates valued productivity costs according to the human
capital approach [35, 36, 41, 44–46, 50, 54]; 13 applied
both the human capital and the friction costs approach [33,
34, 53]. As expected, studies applying the human capital
approach generated higher productivity costs, since in the
friction cost approach the duration of inclusion of pro-
ductivity loss is shorter. For studies applying the human
capital approach, productivity costs on average comprised
45 % (range -106 to 83 %) of total costs. Productivity
costs for the 13 estimates for which both the methods were
applied were on average 24 % (range 4–38 %) of the total
with the friction cost approach, and 44 % (range -106 to
80 %) with the human capital approach. For the study in-
cluding unpaid labour costs [33], these costs were on av-
erage 0.7 % of the total, ranging from -25 % (i.e., led to
savings) to 15 %, depending on the study arm.
The impact of productivity costs on cost-
effectiveness outcomes
To study the impact of productivity costs on cost-effec-
tiveness outcomes, the ICERs, including productivity cost,
were recalculated after excluding these costs in the ana-
lyses. Since CMAs obviously do not present ICERs, given
the assumption of equal effectiveness between comparators,
we recalculated the cost differences after excluding pro-
ductivity costs. Because only one study considered unpaid
labour, we limited our calculations to paid labour only.
Recalculation of cost-effectiveness outcomes was only
possible for the 15 CUAs and three CMAs (representing a
total of 36 ICERs and eight incremental cost calculations)
specifying the amount of productivity costs, or the effect of
productivity costs on the ICER. The change in incremental
cost-effectiveness after excluding productivity costs is
shown in Fig. 2. For all ICERs two bars are included. The
first reflects the incremental cost-effectiveness in 2009 eu-
ros per QALY excluding productivity costs; the second
reflects the incremental cost-effectiveness including pro-
ductivity costs. The incremental costs of the three CMAs
are presented on the right-hand side of the vertical line in
Fig. 2. Productivity cost exclusion had little effect on the
incremental costs in these studies. For six of the eight cal-
culations, the incremental costs were close to zero with and
without productivity costs. As a result, the bars representing
the incremental costs in Fig. 2 are hardly visible.
We drew two fictive ICER thresholds in the figure for
illustrative purposes: one at approximately €40,000 per
incremental QALY in the region of the upper limit of the
UK costs per QALY threshold [55] and one at €80,000, a
suggested threshold for diseases with a very high burden of
disease by the Dutch Council for Public Health and Health
Care [56]. These threshold lines illustrate how productivity
cost inclusion (exclusion) potentially affects decision-
making for treatments where the ICER with productivity
cost falls below (above) the threshold and the ICER
without productivity costs above (below) the threshold.
Note that we did not include uncertainty around the ICERS
and the thresholds.
A comparison of ICERs with the inclusion and exclu-
sion of productivity costs shows that ICERs increase due to
inclusion of productivity costs in six out of 36 cases [53,
54]. In four of these cases the new treatment changed from
cost-saving to cost-spending [54]. Including productivity
costs led to a decrease of the IC(ER) in 30 cases [33, 37,
38, 41, 43–46, 48–53]. In six of these 30 cases the decrease
caused the incremental costs to change from positive to
negative, therefore turning the new treatment into a cost-
saving intervention [33, 37, 48, 51].
Taking into account the fictive threshold of €40,000 per
QALY, eight ICERs exceed the threshold when excluding
productivity costs, while not exceeding the threshold when
including productivity costs [33, 37, 41, 51, 52]. The other
way around, three ICERs lie below the €40,000 threshold
without productivity costs and exceed this threshold after
including productivity costs [54]. In other words, in 11 of
the 36 ICERs (31 %) including or excluding productivity
costs would alter decision-making (if exclusively based on
an ICER decision rule), based on a fixed €40,000 threshold.
If we raise the threshold to €80,000, three ICERs exceed
the threshold as a consequence of excluding productivity
costs [33, 38]. With the €80,000 threshold, none of the
ICERs is above the threshold including productivity costs
and below the threshold after excluding these costs. With
an €80,000 threshold, decision-making could alter in three
of 36 cases (8 %).
Discussion
This study investigated productivity cost inclusion and its
impact on cost-effectiveness outcomes in economic
evaluations of very expensive drugs. Moreover, the applied
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methodology regarding productivity cost measurement and
valuation was assessed and possible explanatory factors for
exclusion of these costs were explored. The results showed
that productivity costs were excluded in over 90 % of the
investigated economic evaluations. If productivity costs
were included, the applied methods were mostly poorly
reported.
Regarding the main objective of this study, determining
whether productivity costs have a substantial impact on
cost-effectiveness outcomes, when productivity costs were
actually included this was clearly the case. Despite the high
direct costs related to expensive drug treatment, produc-
tivity costs reflect a relatively high proportion of total costs
and can strongly affect incremental cost-effectiveness ra-
tios. With a fixed €40,000 threshold (somewhere in the
region of the upper limit of the UK threshold [55]), deci-
sions regarding reimbursement of expensive drugs could
alter in almost one-third of the cases by including or ex-
cluding productivity costs in the cost-effectiveness
analyses. In other words, the upcoming shift in perspective
in the UK may have a strong impact on subsequent deci-
sion-making. The exact influence of productivity cost in-
clusion does not only depend on the methodology used to
estimate productivity costs (and whether or not consump-
tion is included [57]), it also depends on the decision
framework. If the decision framework assumes a fixed
budget and, hence, displacement of current health inter-
ventions, the productivity gains or losses related to these
displaced activities could also be included in the evaluation
[8].
Given the potential strong effects of productivity costs
on final outcomes, productivity costs cannot be simply
excluded in economic evaluations of expensive hospital
drugs based on ‘the rule of reason’ introduced by Gold
et al. [6]. Nevertheless, only one of the 249 identified
economic evaluations included productivity costs related to
both paid and unpaid work, and 21 (8 %) singly included
productivity costs related to paid work. Such results
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indicate that productivity costs related to unpaid work
rarely seem to play a role in cost-effectiveness calculations
of expensive drugs administered in the hospital, and pro-
ductivity costs related to paid work are ignored in the vast
majority of studies. When we compare our findings to
findings of previous studies [11–13], it seems that pro-
ductivity cost inclusion (or rather exclusion) has not
changed over recent decades.
A secondary objective of our study was to determine the
extent to which productivity costs inclusion or exclusion is
related to patients’ ages, severity of illness and countries’
health economic reimbursement submission guidelines.
Assuming that an average study-population age below 70
implies that a considerable number of the patients are still
of working age, age does not seem to explain the exclusion
of productivity costs in economic evaluations of expensive
hospital drugs. Health status may be of influence, however.
In approximately one-third of the studies, the severity of
illness of the patients could have been a reason for ex-
cluding productivity costs (related to paid work) up front.
Moreover, our results indicate that health economic
guidelines influence productivity cost inclusion or exclu-
sion, but most guidelines leave room for judging when to
include productivity costs and how to do so. Several studies
did not seem to adhere to their national corresponding
guidelines. Partly, this may be explained by some studies
not being conducted for reimbursement submission pur-
poses; however, such information was not presented in the
papers. It is unclear what the consequences are of not ad-
hering to national guidelines. Likely this differs between
countries. Notably, in most of the studies we examined,
clear information on how productivity costs were derived
was lacking. It has been suggested that the decision to
include productivity costs may be driven by strategic
considerations regarding the expected influence on final
outcomes, resulting in a selection-perspective bias [11].
Although too few studies in our review included produc-
tivity costs to be able to confirm this suggestion, the ICERs
of every economic evaluation that included productivity
costs against the relevant health economic guidelines de-
creased. The existence of a selection-perspective bias em-
phasizes the importance of standardizing economic
evaluations. Given the large impact of productivity costs,
transparency in measurement and valuation methods is
paramount. Studies’ comparability, completeness and
transferability would be served by consistent and prefer-
ably uniform inclusion of productivity costs, perhaps pre-
sented as a separate item. Inclusion also raises decision
makers’ awareness of societal costs (or savings). If these
costs are for any reason not included, it is important to
justify their exclusion.
A limitation of our review is that by necessity we
assessed the impact of productivity costs on cost-
effectiveness outcomes based on the studies that actually
included them. The amount of productivity costs in these
studies may poorly reflect productivity costs in studies
excluding these costs, especially if based on strategic
considerations. Moreover, we were unable to determine
how inclusion or exclusion of productivity costs related to
unpaid work affects cost-effectiveness outcomes, since
only one economic evaluation in our review considered
unpaid work. Finally, we did not study or discuss the im-
pact of the lack of scientific consensus regarding appro-
priate methods of measuring and valuing productivity costs
on the exclusion of these costs. Numerous instruments, for
example, can measure productivity costs (mainly related to
paid work) but which instrument provides the most valid
estimate is currently unknown. Estimates that vary sub-
stantially [58, 59] by using different instruments can result
in a lack of confidence in the trustworthiness of produc-
tivity cost estimates. Given the fact that the studies in our
review used a variety of measurement instruments, this is
an important concern.
Next to measurement difficulties, the valuation of pro-
ductivity costs (related to paid work) has been fiercely
debated [23, 60–64]. The suitability of three valuation
approaches has dominated the debates: the human capital
approach, [22] the friction cost approach, [23] and the
Washington panel approach [6]. For more information on
the valuation approaches and the debates, see Tilling et al.
[65] or Nyman [64]. The Washington panel approach re-
ceived little theoretical and practical support, but lack of
consensus on whether to apply the friction cost or the hu-
man capital approach translates to the use of both in
practice [11, 13, 66].
Conclusion
Productivity costs lead to noticeable differences in cost-
effectiveness outcomes of economic evaluations of treat-
ments with expensive hospital drugs. Despite the high di-
rect costs related to the drugs, productivity costs reflect a
non-negligible part of total costs when included and,
therefore, a priori exclusion of productivity costs is not
easy to defend when adopting a societal perspective. Ig-
noring productivity costs in economic evaluations of ex-
pensive hospital drugs without clear motive could imply
ignoring important societal costs. That notwithstanding,
productivity costs related to paid work are omitted in the
majority of cases and productivity costs related to unpaid
work are seldom included. The neglect of productivity
costs is to some extent explained by the relevant national
health economic guidelines prescribing a health care per-
spective, but the rationale for the majority of studies is
unclear. We would argue that if productivity costs are
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ignored, motivation should be clear. Moreover, excluding
productivity costs simply to comply with national guide-
lines does not render them less relevant to society or
welfare improvement. Therefore, in countries prescribing a
health care perspective a two-perspective approach, in
which ICERs are presented from both a societal and health
care perspective (as was done by some studies in this re-
view), may be advisable [14].
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